Alpine Global Management’s Royalty Pharma RPRX Stock Holding History

Alpine Global Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,040	Closed	-$543K	–	393
2025 Q4	$543K	Sell	14,040 -501	-3%	-$19.1K	0.12%	97
2025 Q3	$513K	Buy	+14,541	New	+$526K	0.1%	90
2022 Q1	–	Sell	-17,286	Closed	-$689K	–	680
2021 Q4	$689K	Buy	+17,286	New	+$672K	0.1%	226

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Alpine Global Management's RPRX Position: Q1 2026 in Review

Alpine Global Management sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 14,040 shares — an estimated $543K sold.

Alpine Global Management first reported a position in RPRX in Q4 2021 and held it in 3 quarters. The position peaked at $689K in Q4 2021. 590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Alpine Global Management reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Alpine Global Management sold 14,040 Royalty Pharma shares in Q1 2026, an estimated $543K.
Alpine Global Management first reported a position in Royalty Pharma in Q4 2021 and held it in 3 quarters.
Alpine Global Management's Royalty Pharma position peaked at $689K in Q4 2021.
590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Alpine Global Management's 13F filing for Q1 2026, filed 15 May 2026.